Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial
Published in JAMA, this crossover randomized controlled trial demonstrates glycemic improvements with Dexcom continuous glucose monitoring (CGM) use in patients with T1D treated with multiple daily injections (MDI) insulin therapy and is the first major study to show improvements in key quality of life (QoL) measures.
Study highlights include:
- 0.43% average A1C reduction for CGM group compared to conventional therapy ( blood glucose meter [BGM])
- 3 times many patients in the CGM group showed an average A1C reduction >1.0% compared to conventional therapy
- 80% average decrease in severe hypoglycemia for those in the CGM group (defined as requiring assistance from another person or resulting in unconsciousness)
Source: Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-387.
The clinical benefits of real time continuous glucose monitoring (rtCGM) use have been well demonstrated in both continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI)...
In this novel study, investigators examined not only the benefits of continuous glucose monitoring (CGM) augmented insulin therapy, they also looked at the impact of CGM separately in subjects on...